Key facts
- It has raised $113.3M; the latest was Grant ($2.1M) in Nov 2024.
- Notable investors include Gates Foundation, Participatiemaatschappij Vlaanderen, Astanor, Korys Investments, Société Fédérale de Participations et d'Investissement — 22 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 22 names
- ·Watchlist + deal alerts for Aphea.Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Aphea.Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Aphea.Bio
Developer of innovative biological products designed to promote sustainable agriculture by enhancing crop protection and soil vitality. The company offers a diverse range of natural biostimulants and biocontrol products, enabling farmers across conventional farming systems to increase crop resilience, protect yields, and improve overall soil health.
- Sector
- Healthcare
- HQ
- Gent, Belgium
- Founded
- 2017
- Employees
- 77
- Website
- aphea.bio/
- Ownership
- Privately Held (backing)
Aphea.Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Aphea.Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Aphea.Bio in its N-PORT filings yet. We sweep new filings monthly.